Home > News > BioSante Pharmaceuticals Reports Product Development Highlights
May 16th, 2005
BioSante Pharmaceuticals Reports Product Development Highlights
Abstract:
BioSante Pharmaceuticals (AMEX:BPA) today reported on certain product development highlights and announced financial results for the first quarter ended March 31, 2005.
"The completion of our pivotal Phase III clinical trial of Bio-E-Gel(TM) and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer.
Source:
genengnews.com
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||